切换至 "中华医学电子期刊资源库"

中华眼科医学杂志(电子版) ›› 2021, Vol. 11 ›› Issue (01) : 41 -47. doi: 10.3877/cma.j.issn.2095-2007.2021.01.007

论著

柚皮素对人角膜上皮细胞毒性的实验研究
李豪亮1, 朱然1, 张希熹1, 梁舒1,()   
  1. 1. 226001 南通大学附属医院眼科
  • 收稿日期:2020-10-22 出版日期:2021-02-28
  • 通信作者: 梁舒
  • 基金资助:
    江苏省卫健委医学科研面上项目(H2019083)

The toxicity of naringenin to human corneal epithelial cells

Haoliang Li1, Ran Zhu1, Xixi Zhang1, Shu Liang1,()   

  1. 1. Department of Ophthalmology, Affiliated Hospital of Nantong University, Nantong 226001, China
  • Received:2020-10-22 Published:2021-02-28
  • Corresponding author: Shu Liang
引用本文:

李豪亮, 朱然, 张希熹, 梁舒. 柚皮素对人角膜上皮细胞毒性的实验研究[J/OL]. 中华眼科医学杂志(电子版), 2021, 11(01): 41-47.

Haoliang Li, Ran Zhu, Xixi Zhang, Shu Liang. The toxicity of naringenin to human corneal epithelial cells[J/OL]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2021, 11(01): 41-47.

目的

探讨柚皮素(Nar)对人角膜上皮细胞(HCECs)的毒性。

方法

对购于青旗上海生物技术发展有限公司的HCECs进行细胞毒性实验和划痕实验。应用四氮唑盐比色分析法检测二甲基亚砜(DMSO)溶剂和Nar对HCECs细胞存活率的影响,采用Graphpad Prism8.0软件绘制细胞存活率曲线并计算半抑制浓度(IC50)。应用划痕实验观察不同浓度Nar对HCECs迁移的影响,采用ImageJ软件计算细胞的愈合率。吸光度值、存活率及愈合率数值符合正态分布,均采用均数±标准差表示。不同浓度的DMSO溶剂和Nar溶液对HCECs 24 h、48 h及72 h存活率的比较;不同浓度Nar对HCECs 6 h、12 h及24 h划痕愈合率的比较,均采用独立样本t检验。

结果

体积百分比为0.04%、0.08%及0.16%的DMSO处理HCECs 24 h,其存活率分别为(94.57±0.83)%、(93.59±1.17)%及(91.43±1.47)%。经t检验,各浓度DMSO处理HCECs 24 h,其存活率与DMEM(dulbecco′s modified eagle medium)组比较的差异均有统计学意义(t=3.436,3.882,4.960;P<0.05)。体积百分比为0.08%和0.16%的DMSO处理HCECs 48 h,其存活率分别为(94.43±0.38)%和(93.16±0.66)%。经t检验,各浓度DMSO处理HCECs 48 h,其与DMEM组比较存活率的差异均有统计学意义(t=2.953,3.573;P<0.05)。体积百分比为0.02%、0.04%、0.08%及0.16%的DMSO处理HCECs 72 h,其存活率分别为(96.28±0.29)%、(95.30±0.25)%、(94.65±0.82)%及(93.73±1.18)%。经t检验,各浓度DMSO处理HCECs 72 h,其与DMEM组比较存活率的差异均有统计学意义(t=3.756,4.763,4.929,5.263;P<0.05)。200 μM、400 μM及800 μM Nar溶液处理HCECs 48 h,其存活率分别为(60.17±0.46)%、(47.55±0.91)%及(29.19±1.25)%;72 h的存活率分别为(60.02±6.20)%、(31.20±1.96)%及(22.96±2.69)%。经t检验,各浓度Nar处理HCECs 48 h和72 h,其与24 h比较存活率的差异均有统计学意义(t=12.903,6.675, 11.215,5.377,12.696,11.972;P<0.05)。25 μM、400 μM及800 μM Nar溶液处理HCECs 72 h,其存活率分别为(89.41±1.38)%、(31.20±1.96)%及(22.96±2.69)%。经t检验,各浓度Nar溶液处理HCECs 72 h,其与48 h比较存活率的差异均有统计学意义(t=4.442,13.119,3.631;P<0.05)。Nar溶液对HCECs 24 h、48 h及72 h的IC50分别为690.8 μM、343.4 μM及237.7 μM;IC50 95%可信区间分别为(574.1~845.5)、(259.2~734.3)及(231.1~266.7)。HCECs在0、100 μM、200 μM及400 μM Nar溶液中HCECs 6 h的划痕愈合率分别为(18.04±1.61)%、(16.91±1.56)%、(16.63±2.12)%及(12.20±2.06)%。划痕愈合的时间越长,HCECs的愈合率越高。细胞在100 μM Nar溶液浓度中各时间段的划痕愈合率与DMEM组比较的差异均无统计学意义(t=0.872,1.074,1.620;P>0.05);400 μM Nar溶液各时间段的划痕愈合率与DMEM组比较的差异均有统计学意义(t=3.863,9.869,27.194;P<0.05);200 μM Nar溶液处理HCECs 12 h和24 h,其划痕愈合率与DMEM组比较的差异均有统计学意义(t=5.714,9.119;P<0.05)。

结论

Nar可降低HCECs存活率并抑制HCECs迁移愈合率,对HCECs具有毒性。

Objective

The aim of this study was to investigate the toxicity of naringenin (Nar) to human corneal epithelial cells (HCECs).

Methods

HCECs purchased from Qingqi Shanghai Biotechnology Development Co., Ltd. were used for cytotoxicity test and scratch test. The tetrazolium salt colorimetric assay was used to detect the cell survival of Nar and DMSO on HCECs. Graphpad Prism8.0 software was used to map the cells survival curve and calculate the half inhibitory concentration (IC50). The scratch experiment was used to observe the effect of different concentrations of Nar on the migration of HCECs. ImageJ was used to calculate the cell healing rate (HR). OD value, survival rate (SR) and HR were in accordance with normal distribution, and expressed by ±s.The independent sample t-testing method was used to compare SR of HCECs with different concentrations of DMSO solvent and Nar solution for 24 h, 48 h and 72 h; and the wound HR of cells at 6 h, 12 h and 24 h with different concentrations of Nar.

Results

The SR of HCECs in the DMSO 0.04%, 0.08% and 0.16% groups for 24 h was (94.57±0.83)%, (93.59±1.17)% and (91.43±1.47)%, respectively. After t testing, compared with the DMEM group, the difference in the SR of HCECs was statistically significant (t=3.436, 3.882, 4.960; P<0.05). The SR of HCECs was (94.43±0.38)% and (93.16±0.66)% in the DMSO group with a volume percentage of 0.08% and 0.16% for 48 h. After t testing, compared with the DMEM group, the difference in the SR of HCECs was statistically significant (t=2.953, 3.573; P<0.05). In the DMSO group with the volume percentage of 0.02%, 0.04%, 0.08% and 0.16% for 72 h, the SRs of HCECs were (96.28±0.29)%, (95.30±0.25)%, (94.65±0.82)% and (93.73±1.18)%. After t testing, the difference in the SR of HCECs between different DMSO volume percentage and the DMEM group was statistically significant (t=3.756, 4.763, 4.929, 5.263; P<0.05). The SRs of HCECs treated with 200 μM, 400 μM and 800 μM Nar solutions for 48 h were (60.17±0.46)%, (47.55±0.91)% and (29.19±1.25)%, respectively; the SRs at 72 h were ( 60.02±6.20)%, (31.20±1.96)% and (22.96±2.69)%. After t testing, the difference in SR of HCECs for 48 h and 72 h compared with that for 24 h, was statistically significant (t=12.903, 6.675, 11.215, 5.377, 12.696, 11.972; P<0.05). The SRs of HCECs treated with 25 μM, 400 μM and 800 μM Nar solutions for 72 h were (89.41±1.38)%, (31.20±1.96)% and (22.96±2.69)%, respectively. After t testing, the SR of HCECs for 72 h compared with that for 48 h was significantly different (t=4.442, 13.119, 3.631; P<0.05). The IC50 of Nar solution for HCECs at 24 h, 48 h and 72 h was 690.8 μM, 343.4 μM and 237.7 μM, respectively, and the 95% confidence intervals of IC50 were (574.1 to 845.5), (259.2 to 734.3) and (231.1 to 266.7). The migration area coverage rate of HCECs for 6 h in 0, 100 μM, 200 μM and 400 μM Nar solutions were (18.04±1.61)%, (16.91±1.56)%, (16.63±2.12)% and (12.20±2.06) %, respectively. The migration area coverage rate of HCECs gradually increased with time. Compared with the DMEM group, there was no significant difference in the migration area coverage rate of cells added with 100 μM Nar solution in per time period (t=0.872, 1.074, 1.620; P>0.05); the difference in that of cells added with 400 μM Nar was statistically significant (t=3.863, 9.869, 27.194; P<0.05); the difference in the scar HR of HCECs added with 200 μM Nar after scratching for 12 h and 24 h was significantly different (t=5.714, 9.119; P<0.05).

Conclusions

Nar could reduce the SR of HCECs and inhibit the migration and HR of HCECs, which is toxic to HCECs.

表1 不同浓度二甲基亚砜中24 h、48 h及72 h细胞存活率的比较(±s)
图4 倒置光学显微镜下人角膜上皮细胞在不同浓度柚皮素各时间段内划痕愈合后的形态(100×) 4A~4D分别示实验初始时人角膜上皮细胞在柚皮素0、100 μM、200 μM及400 μM浓度下的形态;4E~4K分别示划痕6 h后人角膜上皮细胞在柚皮素0、100 μM、200 μM及400 μM浓度下的愈合后形态;4L~4O分别示划痕12 h后人角膜上皮细胞在柚皮素0、100 μM、200 μM及400 μM浓度下的愈合后形态;4P~4S分别示划痕24 h后人角膜上皮细胞在柚皮素0、100 μM、200 μM及400 μM浓度下的愈合后形态
表2 不同浓度柚皮素溶液中24 h、48 h及72 h细胞存活率的比较(±s)
[1]
王元,曾凯宏,邓波,等. 柚皮素对高糖模型MIN6细胞的增殖和胰岛素分泌的影响[J]. 重庆医学202049(17): 2844-2848.
[2]
Shi R, Su WW, Zhu ZT, et al. Regulation effects of naringin on diesel particulate matter-induced abnormal airway surface liquid secretion[J]. Phytomedicine, 2019, 63: 153004.
[3]
Lou C, Zhang F, Yang M, et al. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells[J]. PLoS One, 2012, 7(12): e50956.
[4]
曾文峰,张发云,杜刚军,等. 柚皮素:新一代免疫调节剂[J]. 生物化学与生物物理进展201845(9): 915-925.
[5]
Lin J, Sun J, Wang Y, et al. Ocular pharmacokinetics of naringenin eye drops following topical administration to rabbits[J]. J Ocul Pharmacol Ther, 2015, 31(1): 51-56.
[6]
魏爽,盛敏杰,姜亚萍,等. 药物毒性角膜病变的研究进展[J]. 眼科新进展201939(10): 988-991.
[7]
Duda-Madej A, Kozowska J, Krzyžek P, et al. Antimicrobial O-Alkyl derivatives of naringenin and their oximes against multidrug-resistant bacteria[J]. Molecules, 2020, 25(16): 3642.
[8]
张晓燕,张慧芝,陈梦平,等. 某院2013—2016年抗菌药物眼用制剂使用量与眼部感染细菌耐药性分析[J]. 中国药房201728(26): 3634-3638.
[9]
Lin Y, Tan D, Kan Q, et al. The protective effect of naringenin on airway remodeling after mycoplasma pneumoniae infection by inhibiting autophagy-mediated lung inflammation and fibrosis[J]. Mediators Inflamm, 2018: 8753894.
[10]
Zhang C, Zeng W, Yao Y, et al. Naringenin ameliorates radiation-induced lung injury by lowering IL-1β level[J]. J Pharmacol Exp Ther, 2018, 366(2): 341-348.
[11]
Manchope MF, Artero NA, Fattori V, et al. Naringenin mitigates titanium dioxide (TiO2)-induced chronic arthritis in mice: role of oxidative stress, cytokines, and NFκB[J]. Inflamm Res, 2018, 67(11-12): 997-1012.
[12]
Lather A, Sharma S, Khatkar A. Naringenin derivatives as glucosamine-6-phosphate synthase inhibitors: synthesis, antioxidants, antimicrobial, preservative efficacy, molecular docking and in silico ADMET analysis[J]. BMC Chem, 2020, 14(1): 41.
[13]
Huang YF, Bai C, He F, et al. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)[J]. Pharmacol Res, 2020, 158: 104939.
[14]
曲明俐,段豪云,王瑶,等. 三种常用非甾体类抗炎滴眼液对人角膜上皮细胞的毒性研究[J].中华实验眼科杂志201533(7): 627-632.
[15]
魏会宇,赵少贞. 溴芬酸钠滴眼液对角膜上皮细胞的毒性研究及分析[J]. 中国地方病防治杂志201631(8): 959-960.
[16]
Ayaki M. Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells[J]. Clinical Ophthalmology, 2010, 21(4): 1217-1222.
[17]
贺兵,谢晓燕,张枫,等. 不同浓度二甲基亚砜对兔软骨细胞生长的影响[J/CD]. 中华临床医师杂志:电子版20148(9): 79-82.
[18]
Nirogi R, Kandikere V, Bhyrapuneni G, et al. Effect of dimethyl sulfoxide on in vitro cytochrome P4501A2 mediated phenacetin O-deethylation in human liver microsomes[J]. Drug Metab Dispos, 2011, 39 (11): 2162-2164.
[19]
Nishimura M, Ueda N, Naito S. Effects of dimethyl sulfoxide on the gene induction of cytochrome P450 isoforms, UGT-dependent glucuronosyl transferase isoforms, and ABCB1 in primary culture of human hepatocytes[J]. Biol Pharm Bull, 2003, 26(7): 1052-1056.
[20]
刘耳,王金兵. 细胞冻存保护剂二甲基亚砜的细胞毒作用[J]. 中国预防兽医学报199412(4): 50-52.
[21]
杨莉,安益国,郑建忠. 柚皮素诱导肺腺癌A549细胞凋亡的研究[J]. 中国现代医药杂志201416(10): 19-21.
[22]
周跃,周燕红. 柚皮素联合5-FU对大肠癌细胞增殖和迁移的影响[J]. 湖北科技学院学报(医学版)202034(5): 369-372,394.
[23]
夏一萍. 环孢素A在角膜上皮细胞抗真菌免疫中对Dectin-1表达的影响及机制[D]. 青岛:青岛大学,2017.
[24]
周洋,陈婷妍,美丽巴努·玉素甫. 金雀异黄素通过ROS-NLRP3-IL-1β途径保护角膜上皮细胞免受高渗刺激诱导的损伤[J]. 医学研究杂志202049(4): 80-86.
[25]
Ortiz-Andrade RR, Sánchez-Salgado JC, Navarrete-Vázquez G, et al. Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra- pancreatic glucose regulation[J]. Diabetes Obes Metab, 2008, 10(11): 1097-1104.
[26]
李雪弟. 角膜外伤所致真菌性角膜炎误诊原因分析[J]. 中华眼外伤职业眼病杂志199921(4): 358.
[27]
Chen YY, Chang YM, Wang KY, et al. Naringenin inhibited migration and invasion of glioblastoma cells through multiple mechanisms[J]. Environ Toxicol, 2019, 34(3): 233-239.
[28]
李林芳,杨倩,张源源,等. 柚皮素对人与小鼠乳腺癌细胞的增殖、迁移、侵袭及凋亡的影响[J].中国普通外科杂志202029(11): 1346-1356.
[29]
Zhao ZJ, Jin GG, Ge YH, et al. Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways[J]. Inflammopharmacology, 2019, 27(5): 1021-1036.
[30]
Wang H, He Y, Hou Y, et al. Novel self-nanomicellizing formulation based on Rebaudioside A: A potential nanoplatform for oral delivery of naringenin[J]. Mater Sci Eng C Mater Biol Appl, 2020, 112: 110926.
[31]
裴岩岩,闫春生,牛美兰,等. 柚皮素纳米混悬剂的制备及其体内药动学行为[J].中成药201941(9): 2034-2038.
[32]
王建筑,毕研平,李菲,等. 载柚皮素的牛血清白蛋白修饰PLGA纳米粒的制备[J].中成药201941(11): 2566-2571.
[33]
王晓晨,陈莹,刘丁铭,等.柚皮素脂质体的制备及体外释放度的研究[J]. 泰山医学院学报2018, 39(4): 371-373.
[34]
Sandhu PS, Kumar R, Beg S, et al. Natural lipids enriched self-nano-emulsifying systems for effective co-delivery of tamoxifen and naringenin: Systematic approach for improved breast cancer therapeutics[J]. Nanomedicine, 2017, 13(5): 1703-1713.
[1] 卢天祺, 张巍, 周康, 毕士玉, 张羽, 杨秀华. 血流向量成像技术在不同Child-Pugh分级乙肝患者左心功能评价中的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(04): 352-360.
[2] 柯晴潆, 沈延飞, 许强宏, 蔡国龙. 预测脓毒性心肌病患者院内死亡风险列线图模型的构建及验证[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(01): 10-18.
[3] 李文润, 谌莉, 舒畅, 柳随义, 冉永红, 冉新泽, 郝玉徽. 贫铀肾毒性和促排剂的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(01): 83-86.
[4] 江泽莹, 王安婷, 王姣丽, 陈慈, 周秋玲, 黄燕娟, 周芳, 薛琰, 周剑烽, 谭文勇, 杜美芳. 多种植物油组分预防肿瘤放化疗相关毒性反应的效果分析[J/OL]. 中华损伤与修复杂志(电子版), 2023, 18(06): 523-527.
[5] 李敏, 杨世英, 高晓琴, 周丹, 唐筱, 张立婷. 维生素A与慢性肝病相关性研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(02): 65-70.
[6] 潘裕华, 李锐钊, 刘菊娥, 曾英彤, 钟诗龙, 赖伟华. 心脏移植术后急性肾损伤再发低血药浓度他克莫司致慢性肾毒性一例[J/OL]. 中华移植杂志(电子版), 2024, 18(01): 40-44.
[7] 彭祺, 马丽娜, 李倩倩, 陈旭. 重症病毒性肺炎机械通气脱机的影响因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 260-263.
[8] 赵天瑶, 孙英娟, 江晓丹, 李学民. 重视聚维酮碘在白内障手术中的应用与研究[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(02): 65-70.
[9] 唐春雨, 李倩, 郭姗姗, 叶奇, 张丹. 创伤性颅脑损伤神经生理学特征[J/OL]. 中华神经创伤外科电子杂志, 2023, 09(06): 367-371.
[10] 杨东星, 沈鹏, 赵慧颖. 免疫球蛋白联合依库珠单抗治疗GBS 并发重度ARDS 患者一例[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 404-408.
[11] 唐诗, 薛传优, 叶兴, 张鸿举, 戴瑞. 急性病毒性肝炎患者血脂、血糖、蛋白、尿酸变化特点及其与预后的关联[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 396-399.
[12] 宫平, 刘倩, 王啸, 袁会敏, 王维展, 王璞. 早期PI联合Pv-aCO2/Ca-vO2预测老年脓毒性休克的死亡风险[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 253-258.
[13] 崔子豪, 阳跃, 冯光, 郝岱峰, 庹晓晔. Stevens-Johnson综合征/中毒性表皮坏死松解症六例[J/OL]. 中华临床医师杂志(电子版), 2024, 18(01): 30-34.
[14] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J/OL]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
[15] 吕泉龙, 史文杰, 孙文国. 免疫检查点抑制剂在治疗转移性去势抵抗性前列腺癌中的研究进展[J/OL]. 中华诊断学电子杂志, 2024, 12(01): 69-72.
阅读次数
全文


摘要